Display options
Cite
Tave A, Goehring E, Desai V, et al. Risk of interstitial lung disease in patients treated for atrial fibrillation with dronedarone versus other antiarrhythmics. Pharmacoepidemiol Drug Saf. 2021;30(10):1353-1359doi: 10.1002/pds.5233.
Tave, A., Goehring, E., Desai, V., Wu, C., Bohn, R. L., Tamayo, S. G., Sicignano, N., Juhaeri, J., Jones, J. K., & Weiss, S. R. (2021). Risk of interstitial lung disease in patients treated for atrial fibrillation with dronedarone versus other antiarrhythmics. Pharmacoepidemiology and drug safety, 30(10), 1353-1359. https://doi.org/10.1002/pds.5233
Tave, Arlene, et al. "Risk of interstitial lung disease in patients treated for atrial fibrillation with dronedarone versus other antiarrhythmics." Pharmacoepidemiology and drug safety vol. 30,10 (2021): 1353-1359. doi: https://doi.org/10.1002/pds.5233
Tave A, Goehring E, Desai V, Wu C, Bohn RL, Tamayo SG, Sicignano N, Juhaeri J, Jones JK, Weiss SR. Risk of interstitial lung disease in patients treated for atrial fibrillation with dronedarone versus other antiarrhythmics. Pharmacoepidemiol Drug Saf. 2021 Oct;30(10):1353-1359. doi: 10.1002/pds.5233. Epub 2021 May 04. PMID: 33730412; PMCID: PMC8453764.
Copy Download .nbib Format: NLM
Share it on

Pharmacoepidemiol Drug Saf. 2021 Oct;30(10):1353-1359. doi: 10.1002/pds.5233. Epub 2021 May 04.

Risk of interstitial lung disease in patients treated for atrial fibrillation with dronedarone versus other antiarrhythmics.

Pharmacoepidemiology and drug safety

Arlene Tave, Earl Goehring, Vibha Desai, Chuntao Wu, Rhonda L Bohn, Sally G Tamayo, Nicholas Sicignano, Juhaeri Juhaeri, Judith K Jones, Sheila R Weiss

Affiliations

  1. PharmaLex US Corp, Fairfax, Virginia, USA.
  2. HealthCore, Andover, Massachusetts, USA.
  3. Sanofi Pharmaceuticals, Inc., Bridgewater, New Jersey, USA.
  4. Bohn Epidemiology, Boston, Massachusetts, USA.
  5. Naval Medical Center, Portsmouth, Virginia, USA.
  6. Health ResearchTx, Trevose, Pennsylvania, USA.
  7. Avigilan, LLC, Potomac, Maryland, USA.

PMID: 33730412 PMCID: PMC8453764 DOI: 10.1002/pds.5233

Abstract

PURPOSE: To compare risks of interstitial lung disease (ILD) between patients treated with dronedarone versus other antiarrhythmics.

METHODS: Parallel retrospective cohort studies were conducted in the United States Department of Defense Military Health System database (DoD) and the HealthCore Integrated Research Database (HIRD). Study patients were treated for atrial fibrillation (AF) with dronedarone, amiodarone, sotalol, or flecainide. Propensity score matching was employed to create analysis cohorts balanced on baseline variables considered potential confounders of treatment decisions. The study period of July 20, 2008 through September 30, 2014 included a 1-year baseline and minimum 6 months of follow-up, for patients with drugs dispensed between July 20, 2009 and March 31, 2014. Suspect ILD outcomes were reviewed by independent adjudicators. Cox proportional hazards regression compared risk of confirmed ILD between dronedarone and each comparator cohort. A sensitivity analysis examined the effect of broadening the outcome definition.

RESULTS: A total 72 ILD cases (52 DoD; 20 HIRD) were confirmed among 27 892 patients. ILD risk was significantly higher among amiodarone than dronedarone initiators in DoD (HR = 2.5; 95% CI = 1.1-5.3, p = 0.02). No difference was detected in HIRD (HR = 1.0; 95% CI = 0.4-2.4). Corresponding risks in sotalol and flecainide exposure groups did not differ significantly from dronedarone in either database.

CONCLUSIONS: ILD risk among AF patients initiated on dronedarone therapy was comparable to or lower than that of amiodarone initiators, and similar to that of new sotalol or flecainide users. This finding suggests that elevated ILD risk associated with amiodarone does not necessarily extend to dronedarone or other antiarrhythmic drugs.

© 2021 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd.

Keywords: amiodarone; antiarrhythmia agents; atrial fibrillation; dronedarone; interstitial; lung diseases

References

  1. J Atr Fibrillation. 2013 Dec 31;6(4):890 - PubMed
  2. Respir Med. 2014 Apr;108(4):638-46 - PubMed
  3. Korean J Intern Med. 2014 Nov;29(6):746-53 - PubMed
  4. Circ J. 2007 Oct;71(10):1610-6 - PubMed
  5. Am J Ther. 2006 Jul-Aug;13(4):315-9 - PubMed
  6. Am J Cardiol. 1990 May 15;65(18):1185-91 - PubMed
  7. N Engl J Med. 2012 Jan 12;366(2):120-9 - PubMed
  8. Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:256-60 - PubMed
  9. Pharmacoepidemiol Drug Saf. 2021 Oct;30(10):1353-1359 - PubMed
  10. J Clin Pharmacol. 1995 Apr;35(4):351-6 - PubMed
  11. Stroke. 1991 Aug;22(8):983-8 - PubMed

Publication Types

Grant support